Volume 23 Issue 3
Mar.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(3): 401-405
DUAN Jinjiang*, LIU Xingyu, ZHAO Xu, ZHOU Kai, SHEN Qiyang. Comprehensive analysis between ferroptosis-related gene signatures and neuroblastoma prognosis[J]. Chinese Journal of General Practice, 2025, 23(3): 401-405. doi: 10.16766/j.cnki.issn.1674-4152.003913
Citation: DUAN Jinjiang*, LIU Xingyu, ZHAO Xu, ZHOU Kai, SHEN Qiyang. Comprehensive analysis between ferroptosis-related gene signatures and neuroblastoma prognosis[J]. Chinese Journal of General Practice, 2025, 23(3): 401-405. doi: 10.16766/j.cnki.issn.1674-4152.003913
shu

Comprehensive analysis between ferroptosis-related gene signatures and neuroblastoma prognosis

doi: 10.16766/j.cnki.issn.1674-4152.003913
  • 1.

    *Department of General Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 KJ2021A0740

 Byycx22091

  • Received Date: 2024-01-06
    Available Online: 2025-05-14
    Abstract
  •   Objective  Neuroblastoma (NB) is a neoplasm that originates from the neural crest cells of the developing embryo. It is one of the most prevalent extracranial malignancies affecting the central nervous system, manifesting as a solid tumor in the pediatric population these tumors typically develop in the adrenal glands or the sympathetic ganglia. The clinical presentation of NB can vary significantly ranging from asymptomatic incidental tumors to widespread metastases accompanied by systemic manifestations. While children diagnosed with clinically stable NB can be successfully treated, those with high-risk NB often have a poor prognosis, even with combination therapy strategies. In order to assess the prognosis of patients with neuroblastoma (NB), there is a need for in-depth study of sensitive biomarkers.  Methods  Gene sequencing and clinicopathological raw data of 126 and 498 cases were obtained from the TARGET and GEO database. We engaged in a discourse on the role of ferroptosis death-related genes (FRGs) as a prognostic biomarker for NB patients. Lasso-Cox regression analysis was utilized to select FRGs related to prognosis. The experiment involved DRD4 gene knockdown in neuroblastoma, and detected the migration and proliferation ability of tumor cells after DRD4 gene knockdown.  Results  In the TARGET cohort, a prognostic prediction model was constructed using a selection of five genes. The risk score was calculated based on the five selected FRGs. Patients were divided into low-risk and high-risk groups according to the median risk score. The high-risk group exhibited a higher relative abundance of immune cells, and the expression of immuno-oncology targets was found to be up-regulated in patients with high-risk scores. Furthermore, the high-risk group exhibited a heightened association with oxidative phosphorylation and MTORC1 signaling. Knockdown of DRD4 significantly reduced the number of surviving cells and inhibited the migration and proliferation of NB.  Conclusion  FRGs have been identified as sensitive biomarkers with the potential to predict the prognosis of patients with NB. These findings underscore the significance of FRGs in the fields of clinical immunotherapy and targeted therapy.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    LIU Z H, ZHANG X Y, XU M, et al. Loss of CASZ1 tumor suppressor linked to oncogenic subversion of neuroblastoma core regulatory circuitry[J]. Cell Death Dis, 2022, 13(10): 871. DOI: 10.1038/s41419-022-05314-6.
    [2]
    ALIBEG M, SAXENA A, SINGH V, et al. Modulatory role of BV6 and chloroquine on the regulation of apoptosis and autophagy in non-small cell lung cancer cells[J]. J Cancer Res Ther, 2023, 19(Supplement): S0. DOI: 10.4103/jcrt.jcrt_816_21.
    [3]
    HUANG F Y, SHI X Q, HU M, et al. Blocking of FGFR4 signaling by F30 inhibits hepatocellular carcinoma cell proliferation through HMOX1-dependent ferroptosis pathway[J]. Eur J Pharmacol, 2024, 970: 176493. DOI: 10.1016/j.ejphar.2024.176493.
    [4]
    YIN J L, ZHAN J T, HU Q X, et al. Fluorescent probes for ferroptosis bioimaging: advances, challenges, and prospects[J]. Chem Soc Rev, 2023, 52(6): 2011-2030. doi: 10.1039/D2CS00454B
    [5]
    PATANÈGT, PUTAGGIO S, TELLONE E, et al. Ferroptosis: emerging role in diseases and potential implication of bioactive compounds[J]. Int J Mol Sci, 2023, 24(24): 17279. DOI: 10.3390/ijms242417279.
    [6]
    YE L L, WEN X Q, QIN J L, et al. Metabolism-regulated ferroptosis in cancer progression and therapy[J]. Cell Death Dis, 2024, 15(3): 196. DOI: 10.1038/s41419-024-06584-y.
    [7]
    CIMINI S, GIACCONE G, TAGLIAVINI F, et al. P301L tau mutation leads to alterations of cell cycle, DNA damage response and apoptosis: evidence for a role of tau in cancer[J]. Biochem Pharmacol, 2022, 200: 115043. DOI: 10.1016/j.bcp.2022.115043.
    [8]
    MOU Y H, WANG J, WU J C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer[J]. J Hematol Oncol, 2019, 12(1): 34. DOI: 10.1186/s13045-019-0720-y.
    [9]
    TAKAHASHI R, KAMIZAKI K, YAMANAKA K, et al. Expression of ferredoxin1 in cisplatin resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin[J]. Oncol Rep, 2023, 49(6): 124. DOI: 10.3892/or.2023.8561.
    [10]
    VILLALPANDO-RODRIGUEZ G, BLANKSTEIN A, KONZELMAN C, et al. Lysosomal destabilizing drug siramesine and the dual tyrosine kinase inhibitor lapatinib induce a synergistic ferroptosis through reduced heme oxygenase-1 (HO-1) levels[J]. Oxid Med Cell Longev, 2019, 2019: 9561281. DOI: 10.1155/2019/9561281.
    [11]
    WANG Y Q, LI C J, ZHUO J M, et al. The detection of divalent iron and reactive oxygen species during ferroptosis with the use of a dual-reaction turn-On fluorescent probe[J]. Mol Imaging Biol, 2023, 25(2): 423-434. doi: 10.1007/s11307-022-01774-6
    [12]
    LI Y C, WANG X, HUANG Z H, et al. CISD3 inhibition drives cystine-deprivation induced ferroptosis[J]. Cell Death Dis, 2021, 12(9): 839. DOI: 10.1038/s41419-021-04128-2.
    [13]
    UBELLACKER J, TASDOGAN A, RAMESH V, et al. Lymph protects metastasizing melanoma cells from ferroptosis[J]. Nature, 2020, 585(7823): 113-118. doi: 10.1038/s41586-020-2623-z
    [14]
    SONG J H, LIU Y H, GUAN X, et al. A novel ferroptosis-related biomarker signature to predict overall survival of esophageal squamous cell carcinoma[J]. Front Mol Biosci, 2021, 8: 675193. DOI: 10.3389/fmolb.2021.675193.
    [15]
    YANG D M, WANG J W, LI C Y, et al. Ferroptosis-related gene model to predict overall survival of papillary thyroid carcinoma[J]. Am J Otolaryngol, 2021, 42(6): 103163. DOI: 10.1016/j.amjoto.2021.103163.
    [16]
    WU C W, STOREY K B. mTOR signaling in metabolic stress adaptation[J]. Biomolecules, 2021, 11(5): 681. DOI: 10.3390/biom11050681.
    [17]
    ZHOU L, CHONG M, LITTMAN D R. Plasticity of CD4+T cell lineage differentiation[J]. Immunity, 2009, 30(5): 646-655. doi: 10.1016/j.immuni.2009.05.001
    [18]
    李福军, 姜涛, 郭力甲, 等. Sestrin 2通过Nrf2/xCT途径减轻七氟醚诱导的HT22细胞铁死亡研究[J]. 中华全科医学, 2021, 19(6): 917-920, 1068. doi: 10.16766/j.cnki.issn.1674-4152.001949

    LI F J, JIANG T, GUO L J, et al. Sestrin 2 extenuates neuronal ferroptosis induced by sevoflurane through the Nrf2/xCT pathway[J]. Chinese Journal of General Practice, 2021, 19(6): 917-920, 1068. doi: 10.16766/j.cnki.issn.1674-4152.001949
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (32) PDF downloads(5) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return